Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Leptin regulation of Hsp60 impacts hypothalamic insulin signaling
André Kleinridders, … , Peter Bross, C. Ronald Kahn
André Kleinridders, … , Peter Bross, C. Ronald Kahn
Published October 1, 2013
Citation Information: J Clin Invest. 2013;123(11):4667-4680. https://doi.org/10.1172/JCI67615.
View: Text | PDF
Research Article Metabolism

Leptin regulation of Hsp60 impacts hypothalamic insulin signaling

  • Text
  • PDF
Abstract

Type 2 diabetes is characterized by insulin resistance and mitochondrial dysfunction in classical target tissues such as muscle, fat, and liver. Using a murine model of type 2 diabetes, we show that there is hypothalamic insulin resistance and mitochondrial dysfunction due to downregulation of the mitochondrial chaperone HSP60. HSP60 reduction in obese, diabetic mice was due to a lack of proper leptin signaling and was restored by leptin treatment. Knockdown of Hsp60 in a mouse hypothalamic cell line mimicked the mitochondrial dysfunction observed in diabetic mice and resulted in increased ROS production and insulin resistance, a phenotype that was reversed with antioxidant treatment. Mice with a heterozygous deletion of Hsp60 exhibited mitochondrial dysfunction and hypothalamic insulin resistance. Targeted acute downregulation of Hsp60 in the hypothalamus also induced insulin resistance, indicating that mitochondrial dysfunction can cause insulin resistance in the hypothalamus. Importantly, type 2 diabetic patients exhibited decreased expression of HSP60 in the brain, indicating that this mechanism is relevant to human disease. These data indicate that leptin plays an important role in mitochondrial function and insulin sensitivity in the hypothalamus by regulating HSP60. Moreover, leptin/insulin crosstalk in the hypothalamus impacts energy homeostasis in obesity and insulin-resistant states.

Authors

André Kleinridders, Hans P.M.M. Lauritzen, Siegfried Ussar, Jane H. Christensen, Marcelo A. Mori, Peter Bross, C. Ronald Kahn

×

Figure 3

HSP60 is a leptin-induced mitochondrial chaperone.

Options: View larger image (or click on image) Download as PowerPoint
HSP60 is a leptin-induced mitochondrial chaperone.
(A) Western blot and ...
(A) Western blot and densitometric analysis of HSP60 in arcuate nuclei of ob/ob mice after saline or leptin treatment. (B) Western blot and (C) densitometric analysis of HSP60 in arcuate nuclei of fasted or refed C57BL/6 mice and serum leptin levels (n = 3 for each group). (D) Gene expression (n = 4 each) and (E) Western blot analysis of HSP60 in SK-N-SH cells after treatment with saline or leptin. This experiment was repeated twice with a total of four for each genotype. (F) Luciferase activity measurement under the control of the human HSP60 promoter after leptin stimulation (n = 4 for each stimulation). (G) ChIP analysis of pSTAT3 after leptin stimulation of the Hsp60 promoter. (H) Western blot analysis of HSP60 in saline- (–) or leptin-treated (+) lysates of SK-N-SH cells transfected with either WT STAT3 or DN STAT3. (I) Gene expression analysis of Hsp60 in arcuate nucleus of control (Ctrl) and leprS1138 mice (s/s) (n = 6 each). Displayed values are the means ± SEM. *P ≤ 0.05; **P ≤ 0.01.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts